Vomiting: Clinical Trials

6 trials for Vomiting, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Terminated 6
Phase 21Terminated 1

Follow Vomiting: new trials by email Literature Review of Vomiting trials Research Report on Vomiting

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis - Breast Cancer, Nausea
Phase 1TerminatedUniversity of Southern California292012-09-042017-11-17
TAP Block for Open Radical Prostatectomy.
Normal saline via TAP catheters, Lidocaine via TAP catheters - Opioid Consumption, Incidence of Nausea and Vomiting
Phase 1TerminatedMcGill University Health Centre/Research Institute of the McGill University Health Centre252010-08-012015-03-17
Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain
methadone hydrochloride, questionnaire administration, management of therapy complications - Nausea and Vomiting, Pain
Phase 1TerminatedNCIC Clinical Trials Group82010-06-172024-02-12
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
Experimental: aprepitant, Experimental: fosaprepitant, Comparator: ondansetron - Chemotherapy-Induced Nausea and Vomiting
Phase 1TerminatedMerck Sharp & Dohme LLC922009-02-052018-09-25
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
fosaprepitant dimeglumine, systemic chemotherapy, survey administration - Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Phase 1 / Phase 2TerminatedOHSU Knight Cancer Institute342008-08-012017-05-09
Cyclophosphamide Drug Interaction Study In Cancer Patients
Oral GW679769, IV Cyclophosphamide 500-700mg/m2 - Nausea and Vomiting, Chemotherapy-Induced
Phase 1TerminatedGlaxoSmithKline252005-08-102017-11-17

Narrower conditions

Nausea (4)  ·  Breast Neoplasms (1)  ·  Pain (1)  ·  Pain, Postoperative (1)  ·  Sleep Wake Disorders (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (6)  ·  Signs and Symptoms (6)  ·  Signs and Symptoms, Digestive (6)  ·  Neurologic Manifestations (2)  ·  Breast Diseases (1)  ·  Mental Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Nervous System Diseases (1)  ·  Pain (1)  ·  Pathologic Processes (1)  ·  Postoperative Complications (1)  ·  Skin Diseases (1)  ·  Skin and Connective Tissue Diseases (1)

Interventions

fosaprepitant (3)  ·  Aprepitant (1)  ·  Cyclophosphamide (1)  ·  Dexamethasone (1)  ·  Granisetron (1)  ·  Lidocaine (1)  ·  Methadone (1)  ·  Neoadjuvant Therapy (1)  ·  Ondansetron (1)  ·  Saline Solution (1)  ·  casopitant (1)

Sponsors

GlaxoSmithKline (1)  ·  McGill University Health Centre/Research Institute of the McGill University Health Centre (1)  ·  Merck Sharp & Dohme LLC (1)  ·  NCIC Clinical Trials Group (1)  ·  OHSU Knight Cancer Institute (1)  ·  University of Southern California (1)

Countries

United States (3)  ·  Canada (2)  ·  New Zealand (1)  ·  Sweden (1)

Top investigators

Agustin Garcia (1)  ·  Bruno Gagnon, MD, MSC (1)  ·  Franco Carli, Professor (1)  ·  Joseph Bubalo, PharmD, BCPS, BCOP (1)  ·  Ray Viola (1)

Results publications

PMID 25770814

NIH funding

P30CA069533 (1)